Form 8-K - Current report:
SEC Accession No. 0001558370-24-013257
Filing Date
2024-10-11
Accepted
2024-10-11 16:05:22
Documents
15
Period of Report
2024-10-08
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K sngx-20241008x8k.htm   iXBRL 8-K 38261
2 EX-10.1 sngx-20241008xex10d1.htm EX-10.1 48581
  Complete submission text file 0001558370-24-013257.txt   220951

Data Files

Seq Description Document Type Size
3 EX-101.SCH sngx-20241008.xsd EX-101.SCH 4030
4 EX-101.DEF sngx-20241008_def.xml EX-101.DEF 3495
5 EX-101.LAB sngx-20241008_lab.xml EX-101.LAB 17258
6 EX-101.PRE sngx-20241008_pre.xml EX-101.PRE 10062
18 EXTRACTED XBRL INSTANCE DOCUMENT sngx-20241008x8k_htm.xml XML 4842
Mailing Address 29 EMMONS DRIVE SUITE B-10 PRINCETON NJ 08540
Business Address 29 EMMONS DRIVE SUITE B-10 PRINCETON NJ 08540 609-538-8200
SOLIGENIX, INC. (Filer) CIK: 0000812796 (see all company filings)

EIN.: 411505029 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-14778 | Film No.: 241367589
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)